[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDT5kZzk7VL1H9Xm-A-eJIL3f9Po65dYdnqY_7RrD_w0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":9,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":32,"rows":39},"Endocyte",[4],29,false,1,2,2671,0,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"Ovarian Cancer",6,{"name":17,"count":18},"Cancer",4,{"name":20,"count":9},"Metastatic Renal Cell Carcinoma",{"name":22,"count":9},"Solid Tumors",{"name":24,"count":9},"Prostate Cancer",{"name":26,"count":9},"Endometrial Cancer",{"name":28,"count":8},"Prostatic Neoplasms, Castration-Resistant",{"name":30,"count":8},"Non Small Cell Lung Carcinoma",[],[33,34,35,36,37,38],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[40,91,124,154,189,248,313,355,394,416,438,460,482,515,533,551,569,587,605,623,641,666,684,708,730,748,766,784,809,827,853],{"intervention":41,"totalTrials":42,"cells":43},"EC145",3,{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":73,"PHASE4":87,"NA":89},{"trials":45,"activeCount":11},[],{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[50,59],{"nctId":51,"briefTitle":52,"status":53,"phases":54,"primaryCompletion":55,"completion":55,"start":56,"enrollment":8,"conditions":57,"interventions":58},"NCT01002924","Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)","COMPLETED",[35],"2013-12-11","2009-12-31",[22],[41],{"nctId":60,"briefTitle":61,"status":53,"phases":62,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NCT01577654","Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer",[35],"2013-12","2015-08","2011-03",203,[68],"Non Small Cell Lung Cancer",[41,70,71,72],"EC145 + Docetaxel","Docetaxel","EC20",{"trials":74,"activeCount":11},[75],{"nctId":76,"briefTitle":77,"status":78,"phases":79,"primaryCompletion":80,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":85},"NCT01170650","Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)","TERMINATED",[36],"2015-05-31","2015-09-08","2011-04-22",441,[14],[41,86,72],"Pegylated Liposomal Doxorubicin",{"trials":88,"activeCount":11},[],{"trials":90,"activeCount":11},[],{"intervention":72,"totalTrials":42,"cells":92},{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":108,"PHASE3":114,"PHASE4":120,"NA":122},{"trials":94,"activeCount":11},[],{"trials":96,"activeCount":11},[97],{"nctId":98,"briefTitle":99,"status":53,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT00852189","Study of EC0489 for the Treatment of Refractory or Metastatic Tumors",[34],"2011-12","2012-04","2009-04",65,[17],[107,72,107],"EC0489,",{"trials":109,"activeCount":11},[110],{"nctId":60,"briefTitle":61,"status":53,"phases":111,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":112,"interventions":113},[35],[68],[41,70,71,72],{"trials":115,"activeCount":11},[116],{"nctId":76,"briefTitle":77,"status":78,"phases":117,"primaryCompletion":80,"completion":81,"start":82,"enrollment":83,"conditions":118,"interventions":119},[36],[14],[41,86,72],{"trials":121,"activeCount":11},[],{"trials":123,"activeCount":11},[],{"intervention":125,"totalTrials":9,"cells":126},"pegylated liposomal doxorubicin",{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":128,"activeCount":11},[],{"trials":130,"activeCount":11},[],{"trials":132,"activeCount":11},[133],{"nctId":134,"briefTitle":135,"status":53,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":142},"NCT00722592","Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)",[35],"2010-09","2012-12","2008-09",162,[14],[143,125],"Vintafolide",{"trials":145,"activeCount":11},[146],{"nctId":76,"briefTitle":77,"status":78,"phases":147,"primaryCompletion":80,"completion":81,"start":82,"enrollment":83,"conditions":148,"interventions":149},[36],[14],[41,86,72],{"trials":151,"activeCount":11},[],{"trials":153,"activeCount":11},[],{"intervention":155,"totalTrials":9,"cells":156},"177Lu-PSMA-617",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":173,"PHASE4":185,"NA":187},{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[163],{"nctId":164,"briefTitle":165,"status":78,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT03042312","Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy",[35],"2020-01-15","2017-07-12",71,[171],"Metastatic Castration Resistant Prostate Cancer",[155],{"trials":174,"activeCount":11},[175],{"nctId":176,"briefTitle":177,"status":53,"phases":178,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT03511664","Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer",[36],"2021-01-27","2023-12-14","2018-05-29",861,[24],[155],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[],{"intervention":143,"totalTrials":190,"cells":191},5,{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":216,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":193,"activeCount":11},[],{"trials":195,"activeCount":11},[196,207],{"nctId":197,"briefTitle":198,"status":78,"phases":199,"primaryCompletion":200,"completion":200,"start":138,"enrollment":201,"conditions":202,"interventions":204},"NCT01688791","A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)",[34],"2014-09",37,[203],"Advanced Cancer",[143,205,206],"Carboplatin","Paclitaxel",{"nctId":208,"briefTitle":209,"status":78,"phases":210,"primaryCompletion":211,"completion":211,"start":212,"enrollment":42,"conditions":213,"interventions":215},"NCT02049281","A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)",[34],"2014-05","2014-02",[214],"Solid Tumor",[143],{"trials":217,"activeCount":11},[218,222,234],{"nctId":134,"briefTitle":135,"status":53,"phases":219,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":220,"interventions":221},[35],[14],[143,125],{"nctId":223,"briefTitle":224,"status":53,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT00511485","Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)",[35],"2009-07","2009-11","2007-08",43,[231],"Adenocarcinoma of the Lung",[143,233],"Etarfolatide",{"nctId":235,"briefTitle":236,"status":53,"phases":237,"primaryCompletion":103,"completion":103,"start":228,"enrollment":238,"conditions":239,"interventions":240},"NCT00507741","Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)",[35],49,[14,26],[143,241],"Ertafolide",{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[],{"trials":247,"activeCount":11},[],{"intervention":249,"totalTrials":190,"cells":250},"Tc 99m EC20",{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":274,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":252,"activeCount":11},[],{"trials":254,"activeCount":11},[255,265],{"nctId":256,"briefTitle":257,"status":53,"phases":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT01689636","Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients",[34],"2002-07","2000-08",8,[14,263],"Healthy Volunteers",[249],{"nctId":266,"briefTitle":267,"status":53,"phases":268,"primaryCompletion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT01686256","Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer",[34],"2004-08","2001-08",12,[14,26],[249],{"trials":275,"activeCount":11},[276,285,298],{"nctId":277,"briefTitle":278,"status":53,"phases":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT01689662","Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma",[35],"2003-07","2002-08",40,[20],[249],{"nctId":286,"briefTitle":287,"status":53,"phases":288,"completion":289,"start":290,"enrollment":282,"conditions":291,"interventions":297},"NCT01684098","Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor",[35],"2005-08","2003-08",[292,293,294,295,296],"Recurrent or Metastatic Cancer","Head and Neck Cancer","Pancreas Cancer","Bladder Cancer","Testicular Cancer",[249],{"nctId":299,"briefTitle":300,"status":53,"phases":301,"completion":289,"start":290,"enrollment":302,"conditions":303,"interventions":306},"NCT01689714","Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma",[35],16,[304,305],"Ovarian Carcinoma","Recurrent Endometrial Carcinoma",[249],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[],{"trials":312,"activeCount":11},[],{"intervention":233,"totalTrials":42,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":329,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":316,"activeCount":11},[],{"trials":318,"activeCount":11},[319],{"nctId":320,"briefTitle":321,"status":53,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT01748864","Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers",[34],"2013-10","2013-04",23,[327],"Healthy",[233],{"trials":330,"activeCount":11},[331,335],{"nctId":223,"briefTitle":224,"status":53,"phases":332,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":333,"interventions":334},[35],[231],[143,233],{"nctId":336,"briefTitle":337,"status":338,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":11,"conditions":342,"interventions":344},"NCT01953536","Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)","WITHDRAWN",[35],"2016-11","2014-04",[343],"Breast Neoplasms",[345,346,233,347,348],"Vintafolide 2.5 mg","Paclitaxel 80 mg\u002Fm^2","Folic acid","Premedication for Paclitaxel",{"trials":350,"activeCount":11},[],{"trials":352,"activeCount":11},[],{"trials":354,"activeCount":11},[],{"intervention":356,"totalTrials":9,"cells":357},"EC90",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":376,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":359,"activeCount":11},[],{"trials":361,"activeCount":11},[362],{"nctId":363,"briefTitle":364,"status":53,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT00329368","Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer",[34],"2007-12","2008-06","2005-09",13,[17],[356,372,373,374,375],"GPI-0100","EC17","Interleukin-2","Interferon-alpha",{"trials":377,"activeCount":11},[378],{"nctId":379,"briefTitle":380,"status":78,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":271,"conditions":385,"interventions":387},"NCT00485563","A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma",[35],"2008-08","2009-03","2007-06",[386],"Renal Cell Carcinoma",[356,372,373,374,375],{"trials":389,"activeCount":11},[],{"trials":391,"activeCount":11},[],{"trials":393,"activeCount":11},[],{"intervention":372,"totalTrials":9,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":404,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":397,"activeCount":11},[],{"trials":399,"activeCount":11},[400],{"nctId":363,"briefTitle":364,"status":53,"phases":401,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":402,"interventions":403},[34],[17],[356,372,373,374,375],{"trials":405,"activeCount":11},[406],{"nctId":379,"briefTitle":380,"status":78,"phases":407,"primaryCompletion":382,"completion":383,"start":384,"enrollment":271,"conditions":408,"interventions":409},[35],[386],[356,372,373,374,375],{"trials":411,"activeCount":11},[],{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"intervention":373,"totalTrials":9,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[422],{"nctId":363,"briefTitle":364,"status":53,"phases":423,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":424,"interventions":425},[34],[17],[356,372,373,374,375],{"trials":427,"activeCount":11},[428],{"nctId":379,"briefTitle":380,"status":78,"phases":429,"primaryCompletion":382,"completion":383,"start":384,"enrollment":271,"conditions":430,"interventions":431},[35],[386],[356,372,373,374,375],{"trials":433,"activeCount":11},[],{"trials":435,"activeCount":11},[],{"trials":437,"activeCount":11},[],{"intervention":374,"totalTrials":9,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":448,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":441,"activeCount":11},[],{"trials":443,"activeCount":11},[444],{"nctId":363,"briefTitle":364,"status":53,"phases":445,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":446,"interventions":447},[34],[17],[356,372,373,374,375],{"trials":449,"activeCount":11},[450],{"nctId":379,"briefTitle":380,"status":78,"phases":451,"primaryCompletion":382,"completion":383,"start":384,"enrollment":271,"conditions":452,"interventions":453},[35],[386],[356,372,373,374,375],{"trials":455,"activeCount":11},[],{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[],{"intervention":375,"totalTrials":9,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":470,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":463,"activeCount":11},[],{"trials":465,"activeCount":11},[466],{"nctId":363,"briefTitle":364,"status":53,"phases":467,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":468,"interventions":469},[34],[17],[356,372,373,374,375],{"trials":471,"activeCount":11},[472],{"nctId":379,"briefTitle":380,"status":78,"phases":473,"primaryCompletion":382,"completion":383,"start":384,"enrollment":271,"conditions":474,"interventions":475},[35],[386],[356,372,373,374,375],{"trials":477,"activeCount":11},[],{"trials":479,"activeCount":11},[],{"trials":481,"activeCount":11},[],{"intervention":483,"totalTrials":9,"cells":484},"Technetium Tc 99m EC20",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[],{"trials":490,"activeCount":11},[491,500],{"nctId":492,"briefTitle":493,"status":53,"phases":494,"primaryCompletion":495,"start":496,"enrollment":497,"conditions":498,"interventions":499},"NCT01689766","Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma",[35],"2007-11","2003-11",150,[20],[483],{"nctId":501,"briefTitle":502,"status":53,"phases":503,"primaryCompletion":504,"start":505,"enrollment":282,"conditions":506,"interventions":508},"NCT01689727","Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors",[35],"2004-09","2002-09",[507],"Pituitary Tumors",[483],{"trials":510,"activeCount":11},[],{"trials":512,"activeCount":11},[],{"trials":514,"activeCount":11},[],{"intervention":70,"totalTrials":8,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":518,"activeCount":11},[],{"trials":520,"activeCount":11},[],{"trials":522,"activeCount":11},[523],{"nctId":60,"briefTitle":61,"status":53,"phases":524,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":525,"interventions":526},[35],[68],[41,70,71,72],{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"trials":532,"activeCount":11},[],{"intervention":71,"totalTrials":8,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":536,"activeCount":11},[],{"trials":538,"activeCount":11},[],{"trials":540,"activeCount":11},[541],{"nctId":60,"briefTitle":61,"status":53,"phases":542,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":543,"interventions":544},[35],[68],[41,70,71,72],{"trials":546,"activeCount":11},[],{"trials":548,"activeCount":11},[],{"trials":550,"activeCount":11},[],{"intervention":345,"totalTrials":8,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":554,"activeCount":11},[],{"trials":556,"activeCount":11},[],{"trials":558,"activeCount":11},[559],{"nctId":336,"briefTitle":337,"status":338,"phases":560,"primaryCompletion":340,"completion":340,"start":341,"enrollment":11,"conditions":561,"interventions":562},[35],[343],[345,346,233,347,348],{"trials":564,"activeCount":11},[],{"trials":566,"activeCount":11},[],{"trials":568,"activeCount":11},[],{"intervention":346,"totalTrials":8,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":572,"activeCount":11},[],{"trials":574,"activeCount":11},[],{"trials":576,"activeCount":11},[577],{"nctId":336,"briefTitle":337,"status":338,"phases":578,"primaryCompletion":340,"completion":340,"start":341,"enrollment":11,"conditions":579,"interventions":580},[35],[343],[345,346,233,347,348],{"trials":582,"activeCount":11},[],{"trials":584,"activeCount":11},[],{"trials":586,"activeCount":11},[],{"intervention":347,"totalTrials":8,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":590,"activeCount":11},[],{"trials":592,"activeCount":11},[],{"trials":594,"activeCount":11},[595],{"nctId":336,"briefTitle":337,"status":338,"phases":596,"primaryCompletion":340,"completion":340,"start":341,"enrollment":11,"conditions":597,"interventions":598},[35],[343],[345,346,233,347,348],{"trials":600,"activeCount":11},[],{"trials":602,"activeCount":11},[],{"trials":604,"activeCount":11},[],{"intervention":348,"totalTrials":8,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[],{"trials":612,"activeCount":11},[613],{"nctId":336,"briefTitle":337,"status":338,"phases":614,"primaryCompletion":340,"completion":340,"start":341,"enrollment":11,"conditions":615,"interventions":616},[35],[343],[345,346,233,347,348],{"trials":618,"activeCount":11},[],{"trials":620,"activeCount":11},[],{"trials":622,"activeCount":11},[],{"intervention":241,"totalTrials":8,"cells":624},{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":635,"PHASE4":637,"NA":639},{"trials":626,"activeCount":11},[],{"trials":628,"activeCount":11},[],{"trials":630,"activeCount":11},[631],{"nctId":235,"briefTitle":236,"status":53,"phases":632,"primaryCompletion":103,"completion":103,"start":228,"enrollment":238,"conditions":633,"interventions":634},[35],[14,26],[143,241],{"trials":636,"activeCount":11},[],{"trials":638,"activeCount":11},[],{"trials":640,"activeCount":11},[],{"intervention":642,"totalTrials":8,"cells":643},"Vintafolide IV Bolus",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":645,"activeCount":11},[],{"trials":647,"activeCount":11},[648],{"nctId":649,"briefTitle":650,"status":53,"phases":651,"primaryCompletion":228,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":656},"NCT00308269","Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)",[34],"2008-07","2006-03",32,[17],[642,657],"Vintafolide IV",{"trials":659,"activeCount":11},[],{"trials":661,"activeCount":11},[],{"trials":663,"activeCount":11},[],{"trials":665,"activeCount":11},[],{"intervention":657,"totalTrials":8,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":669,"activeCount":11},[],{"trials":671,"activeCount":11},[672],{"nctId":649,"briefTitle":650,"status":53,"phases":673,"primaryCompletion":228,"completion":652,"start":653,"enrollment":654,"conditions":674,"interventions":675},[34],[17],[642,657],{"trials":677,"activeCount":11},[],{"trials":679,"activeCount":11},[],{"trials":681,"activeCount":11},[],{"trials":683,"activeCount":11},[],{"intervention":685,"totalTrials":8,"cells":686},"EC1456 and EC20",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":688,"activeCount":11},[],{"trials":690,"activeCount":11},[691],{"nctId":692,"briefTitle":693,"status":53,"phases":694,"primaryCompletion":695,"completion":696,"start":323,"enrollment":697,"conditions":698,"interventions":699},"NCT01999738","Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors",[34],"2017-12-31","2018-04-26",93,[22,30],[685],{"trials":701,"activeCount":11},[],{"trials":703,"activeCount":11},[],{"trials":705,"activeCount":11},[],{"trials":707,"activeCount":11},[],{"intervention":709,"totalTrials":8,"cells":710},"EC1169",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":712,"activeCount":11},[],{"trials":714,"activeCount":11},[715],{"nctId":716,"briefTitle":717,"status":53,"phases":718,"primaryCompletion":719,"completion":719,"start":211,"enrollment":282,"conditions":720,"interventions":721},"NCT02202447","Phase 1 of EC1169 In Patients With Recurrent MCRPC",[34],"2018-11-29",[24],[709],{"trials":723,"activeCount":11},[],{"trials":725,"activeCount":11},[],{"trials":727,"activeCount":11},[],{"trials":729,"activeCount":11},[],{"intervention":205,"totalTrials":8,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":733,"activeCount":11},[],{"trials":735,"activeCount":11},[736],{"nctId":197,"briefTitle":198,"status":78,"phases":737,"primaryCompletion":200,"completion":200,"start":138,"enrollment":201,"conditions":738,"interventions":739},[34],[203],[143,205,206],{"trials":741,"activeCount":11},[],{"trials":743,"activeCount":11},[],{"trials":745,"activeCount":11},[],{"trials":747,"activeCount":11},[],{"intervention":206,"totalTrials":8,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":751,"activeCount":11},[],{"trials":753,"activeCount":11},[754],{"nctId":197,"briefTitle":198,"status":78,"phases":755,"primaryCompletion":200,"completion":200,"start":138,"enrollment":201,"conditions":756,"interventions":757},[34],[203],[143,205,206],{"trials":759,"activeCount":11},[],{"trials":761,"activeCount":11},[],{"trials":763,"activeCount":11},[],{"trials":765,"activeCount":11},[],{"intervention":107,"totalTrials":8,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":769,"activeCount":11},[],{"trials":771,"activeCount":11},[772],{"nctId":98,"briefTitle":99,"status":53,"phases":773,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":774,"interventions":775},[34],[17],[107,72,107],{"trials":777,"activeCount":11},[],{"trials":779,"activeCount":11},[],{"trials":781,"activeCount":11},[],{"trials":783,"activeCount":11},[],{"intervention":785,"totalTrials":8,"cells":786},"EC0225, for",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":788,"activeCount":11},[],{"trials":790,"activeCount":11},[791],{"nctId":792,"briefTitle":793,"status":53,"phases":794,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT00441870","Study of EC0225 for the Treatment of Refractory or Metastatic Tumors",[34],"2010-11","2007-02",77,[17],[785,800],"99mTC-EC20",{"trials":802,"activeCount":11},[],{"trials":804,"activeCount":11},[],{"trials":806,"activeCount":11},[],{"trials":808,"activeCount":11},[],{"intervention":800,"totalTrials":8,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":812,"activeCount":11},[],{"trials":814,"activeCount":11},[815],{"nctId":792,"briefTitle":793,"status":53,"phases":816,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":817,"interventions":818},[34],[17],[785,800],{"trials":820,"activeCount":11},[],{"trials":822,"activeCount":11},[],{"trials":824,"activeCount":11},[],{"trials":826,"activeCount":11},[],{"intervention":828,"totalTrials":8,"cells":829},"EC1456",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":831,"activeCount":11},[],{"trials":833,"activeCount":11},[834],{"nctId":835,"briefTitle":836,"status":53,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":42,"conditions":841,"interventions":843},"NCT03011320","An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery",[34],"2017-12-30","2018-08-28","2017-01-24",[842],"Ovary Cancer",[828,844],"99mTc-Etarfolatide",{"trials":846,"activeCount":11},[],{"trials":848,"activeCount":11},[],{"trials":850,"activeCount":11},[],{"trials":852,"activeCount":11},[],{"intervention":844,"totalTrials":8,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":856,"activeCount":11},[],{"trials":858,"activeCount":11},[859],{"nctId":835,"briefTitle":836,"status":53,"phases":860,"primaryCompletion":838,"completion":839,"start":840,"enrollment":42,"conditions":861,"interventions":862},[34],[842],[828,844],{"trials":864,"activeCount":11},[],{"trials":866,"activeCount":11},[],{"trials":868,"activeCount":11},[],{"trials":870,"activeCount":11},[]]